




**BIO 2004**

**Annual International  
Convention  
June 6-9 San Francisco**



# AUDIO CDs Presentation Handouts

Presentation Handouts via the web

**Individual session Audio CDs available individually for \$12 each or as a specially priced complete package for \$1349 & save over 40%.**

**Presenter's handouts (downloadable) are available (as provided by the speakers) on line for \$5 each. ([www.softconference.com/240606](http://www.softconference.com/240606))**

**The Complete Set of Handouts are also available on CD-ROM (as provided by the speakers) for \$195 each.**

**Purchase the complete package of Audio CDs bundled with the Handout CD-ROM for \$1495**

## **INDIVIDUAL AUDIO CDs**

- 01...3, 2, 1 . . . Launch!
- 02AB...(\$24/2CDs)...A Rare Perspective: Lessons Learned from Clinical Programs in Ultra Orphan Diseases and Their Broader Applicability
- 04...A Survey of the Antitrust/Intellectual Property Interface in Biotechnology Markets
- 05...Achieving Economies in Patent Protection Without Reducing Deal Value
- 06...Agricultural Biotechnology-A Future to Harvest?
- 07...Animal Biotechnology Products: A New Paradigm in the Regulatory Process
- 08...Animal Extremism-A Growing Threat to Biotechnology
- 09...Apoptosis-Realizing a New Approach to Cancer Treatment
- 10...Averting Crises: How to Lengthen a Company's Financial and Operating Runway
- 11...Beyond "Partner of Choice": Creating Value Through Partnership
- 12AB... (\$24/2CDs).....Beyond FDA Approval: What Strategies Should You Develop for Reimbursement?
- 13.....BioBanking
- 14...Biodefense: Making It Work as Part of Business Strategy
- 15...Bioethics in the Boardroom: The Sequel
- 17...Biopharmaceutical Manufacturing Strategies: Choosing the Right Strategy for the Product and the Company
- 18...Biopharmaceutical Technology Transfer: A Systematic Approach
- 19...Biotech in the Media
- 20...Biotechnology for Small-Molecule Pharmaceutical Manufacturing
- 21...Biotechnology, Innovation and the Global AIDS Epidemic: Treatment Through Technology and Partnership
- 22...Biotech-Pharma Alliance Paradigms
- 23...Blockbusters or Niche Products? How to Balance the Risks and Rewards
- 24...Bugs and Drugs: The Growing Challenge of Resistance
- 25...Can Bankers Spell "DNA"?
- 26...Capitalization and Corporate Opportunity- Securing Federal Resources and Funding for Technology Development
- 27...Clinical Proteomics-New Perspectives on the Use of Biomarkers in Discovery and Development
- 28...Co-Development: A Critical Success Factor for the Biopharma Industry
- 29...Commercialization Opportunities for Nanotechnology in the Life Sciences
- 30...Commercializing Academic Science
- 31...Comparability: Where Do the Agency and the Industry Stand?
- 32...Converging Technologies-Drugs and Medical Devices Combine for Improved Health Care
- 33...Cost-Effective Production of Proteins and Peptides
- 34...Cost-Effectiveness and Therapeutic Products: What Role in Governmental Policy and Decision Making?
- 36...Crossing the Divide: Moving from Early-Stage Biotech to Big Biotech
- 37...Debt Strategies for Extending Your Equity Runway
- 38...Decision-Making Criteria for Biomanufacturing Facility Options
- 39...Department of Defense: Biodefense-Biotechnology Programs
- 40...Designing and Building R&D Facilities Economical for Today and Flexible for the Future
- 41...Developing and Securing Government Funding and Intellectual Property Rights for Products to Combat New Natural and Man-Made Viruses-SARS, Pandemic Influenza, Anthrax and Others: What Works and What Does Not
- 42...Disaster Readiness Plan-The Criticality of Response Planning
- 43...DOE Genomics:GTL: Fueling Biotechnology Solutions to Energy and Climate Challenges
- 44...Doing it Right the First Time: Successful Clinical Trials with CROs
- 45...Drug Development for Minority Populations
- 46...Early-Stage Deal-Making: Issues, Challenges and Innovative Options
- 47...Effective Communications: Building Visibility and Credibility in Competitive Times
- 48...Emerging Biotechnology in China
- 49...Emerging Technologies Enabling Faster Development of Effective Protein Pharmaceuticals
- 50...Emerging Technologies in the Downstream Manufacture of Bio-Materials
- 51...Enforcing Patent Exclusivity In the Global Market-Forums, Issues, Remedies, Costs and Coordination
- 52...Engineered Cellular Products: Tomorrow's Medicine
- 53...Enhancement: Limits of Biotechnology
- 54...Environmental Science-The In-Silico Connection
- 55...Ethics and Science: Understanding the Moral Prism Through Which Americans View Biotechnology
- 56...EU/JUSA-Public Perceptions, Politics and Policy
- 57...Experimental Use: When Does Research Infringe Patents?
- 58...Follow-on Biologics: Now, Later or Never?
- 59...Follow-on Biologics: Scientific Issues
- 60...Food Production Challenges-Nutrition and Sustainability: Can Biotechnology Help?
- 61...Founding Funders: 25 Years of Biotech Venture Capital and Entrepreneurship
- 62...From Acorn to Oak Tree-The Do's and Don'ts of Starting an Emerging Biotech Company
- 63...Gaining Market Position
- 64...Genetic Tests, Pharmacogenomics and Drug Development
- 66...Global Health Issues: New Money, New Players, New Opportunities
- 67...Global Perspectives on Biotechnology
- 68AB... (\$24/2CDs).....Global Regulatory Environment Town Hall Meeting
- 69...GMP Readiness
- 70...Guerrilla Media Tactics-Getting Media Attention Without News
- 71...Harnessing Human Resource Capabilities and Information Technology Prowess: Biotechnology in the Future
- 72...HHS Biodefense Funding and Collaboration Opportunities
- 73...Hot Deals of the Last Year
- 74...Hot Topics
- 75...How Advanced Drug Delivery Technologies Can Help Manage Product Life Cycles Throughout Pharmaceutical Development
- 76...Immunomodulators: Drug Discovery and Development Challenges
- 77...Immunotherapies-Challenges and Opportunities
- 78...Impact of BSE on the Biotech Industry-New Developments in Detection and Risk Assessment
- 79...Impact of the European Clinical Trial Directive for Biotech Companies
- 80...Implementation of the Cartagena Protocol on Biosafety: Challenges for the Biotechnology Sector
- 81...Industrial Biotechnology Opportunities in Chemical Production
- 82...IPO Ultimate Survival Guide
- 83...Is Biotechnology Really Scale Neutral? Growers Around the World Share Perspectives
- 84...Issues Associated with the Development, Clinical Evaluation and Licensing of Vaccines Against Emerging Infections
- 85...Juries Gone Wild: Should Patent Validity Be Decided by Juries?
- 86...Lab Planning
- 87...Latin America Roundtable
- 88...Life Science is from Venus, the Financial Community is from Mars
- 89...Life's a Pitch: Why We're Curmudgeons
- 90...Long-Distance Deals: Forging Success
- 91...Making BioSystems Talk to Microelectronics
- 92...Making Personalized Medicine a Reality
- 94...Managing Growth-Mitigating Risk: Successful Strategies for Competing in a Global Market
- 95...Market Forces and the Development of Successful Licensing Strategies
- 96...Measuring and Maximizing Value Creation
- 97...Mechanics of Investing
- 98...Membrane Proteins as Targets
- 100...Mitigation of Business and Legal Risks in Biodefense Transactions
- 102...Mutually Inclusive: New and Affordable Drugs for Developed, Developing Worlds
- 103...Needle-Free: A Near-Term Solution to Drug Delivery Issues
- 104...New Paradigms, New Tools, New Science: Reflections on Emerging Research Enterprises
- 105...New Routes to Active Ingredients for the Personal Care Market
- 106...New Technologies and Progress in Production of Biopharmaceuticals
- 107...New Wave of Antibodies for Cancer
- 108...New Ways of Doing Business Globally
- 109AB... (\$24/2CDs)...NIH Town Hall
- 111...Opportunities and Challenges in an Expanding European Union
- 112...Outsourcing Roundtable Part 1: Maximizing Value Through Global Manufacturing and Commercialization
- 113...Outsourcing Roundtable Part 2: Maximizing Value Through Global Research and Development

- 114...Pain-Management Advances with Innovative Drug Delivery
- 115...Partnering with Patient-Based Organizations to Achieve Patient Health and Research and Marketing Goals
- 116...Personal and Corporate Liability for Investor Communications: Why You May Be at Risk and How to Minimize the Exposure
- 117...Pharmaceutical Crops, Risk Assessment and Processing Capacity
- 118...Pharmacogenomics in Medicine-Where Are We Today?
- 121...Preapproval Inspections: Preparation, Handling and Follow-Up
- 122...Preservation of Resources-Preservation of Capital and Risk Mitigation with Real Estate and Facilities Strategic Planning
- 123...Products, Platforms or Combination Models: The Investment Rationale
- 124...Progress with Targeted Small-Molecule Cancer Therapies
- 125...Providing Cures for Today and Tomorrow: The Impact of Cross Border Trade in Patented Medicines
- 126...Pulmonary: Advances in Systemic Delivery of Drugs via the Lung
- 127...Quo Vadis Biologicals Manufacturing
- 128...Radioimmunotherapeutics: Expanding the Use of Antibodies Targeting Cancer
- 129...Recent Developments in the Law of Inequitable Conduct
- 130...Regenerative Biology in Medicine
- 131...Regulatory Requirements for the Next Generation of Biotechnology Products
- 132...Repotting Your Products into Fertile Soil: Transferring Products, Programs and Technology Between Companies in Spin-Offs, Carve-Outs, In-Licenses, Acquisitions and Similar Transactions
- 133...RNAi: The New Frontier in Gene Silencing
- 134...Roundtable Discussion-A "Manhattan Project" for Global Disease Prevention?
- 135...Rumors of the Platform Company's Demise are Greatly Exaggerated
- 136...Science and Faith: Agriculture, Medicine and Bioethics from a Religious Perspective
- 137...Set Your Clocks Forward: Timeline to Commercialization
- 138...Show Me the Money-Biotechnology Financing Update
- 139...Skeletons in the Closet or Gold Mines: Issues to Be Considered in Due Diligence Investigations
- 140...Speeding Development of New Therapies that Address Significant Medical Need
- 141...Split Indication Deals: Living with Loose Ends
- 142...Spurring on the One-Trick Pony
- 143...State of the Biotechnology Industry-Circa 2004
- 144...Staying the Course with a Broad Technology
- 145...Stem Cell & Regenerative Medicine: A Critical Update
- 146...Stem Cell Research Advancements and Opportunities
- 147...Stem Cells-From Dreams to Therapeutics
- 148...Sustainable Design and Construction
- 149...Systems Biology: The Need, the Challenge, the Promise
- 150...Targeting the Future of Biotech Drugs by Learning from the Past
- 151...Technical Improvements in Cellulosic Biomass Conversion
- 152...Technology of Advanced Biorefineries
- 153...The Battle for IP: Innovators vs. Generic Drug Makers
- 154...The Biotech & Pharmaceutical Industries in Europe: The Role of National and EU Policies in Their Development
- 155...The Black Box of Deal Valuation: How Do You Know If the Price Is Right?
- 156...The Challenges of Biomanufacturing
- 157...The Challenges of Translational Research Towards the Goal of Personalized Medicine
- 158...The Controlled Spin-Out: How to Move from University PI to Company CEO
- 159...The Convergence of Small- and Large-Molecule Therapeutics in Treating Disease . . . and Its Implications in Deal-Making
- 160...The Evolving Law of Research Tools
- 161...The Finnegan Henderson New Biotechnology Innovation Report
- 162...The Future of Cancer Treatment: Linking Genetics, Genomics and Clinical Endpoints as a Means of Improving Patient Selection and Efficacy Outcomes
- 163...The Future of Clinical Research
- 164...The Future of Meat Production: Designing Foods
- 165...The Golden Braid: Using Synergy Between Internal Development and External Acquisition to Position the Company
- 166...The Impact of Structural Genomics on Drug Discovery
- 167...The Importance of Start-Ups as a Source of Innovation for Established Players in Pharma and Industrial Biotech
- 168...The Management Premium
- 169...The Premier of Ernst & Young's 18th Annual Global Biotechnology Report
- 170...The State of Gene Therapy Today
- 171...The Technology of Drug Discovery
- 172...Tools and Best Practices for Managing an Affordable and Effective Communications Program
- 173...Transforming Drug Discovery Using Clinical Genetics: No More Guesswork
- 174...Transforming Process Development from a Necessary Evil to a Competitive Edge
- 175...Transgenic Systems for Biopharmaceutical Production
- 176...Translational Medicine-Bridging the Gap from University Laboratory to the Clinic
- 178...Tying the Knot: Building on the Relationship
- 181...Universities Are from Venus, Companies Are from Mars
- 182...Using Biotech to Improve Food and Crops-Pacific Rim Challenges in International Trade
- 183...Using the Biotechnology Incubator as a Mechanism for Technology Transfer
- 184...Value Creation in Biotechnology
- 185...Venture Capital and the Mysterious Vanishing "R"-What's Behind the Surge of Interest in Biopharma In-licensing and Development Companies?
- 186...Views from the Hill One Year Later: Patent Legislation and Initiatives
- 188...What Is a Likely Successful Business Model for Personalized Medicine-Big Pharma, Big Biotech or a Specialty Company?
- 189...What's Your Counterfeit Strategy for Your New Product?
- 190...When Is the Time Right for an IPO?
- 191...Why Don't They Love Biotech? Building Crucial Public Support Through Educational Outreach Programs
- 192...Why Immunotherapy Continues to Generate a Buzz After 100 Years
- 193...YES in My Backyard: Mobilizing Regional Resources to Grow Biotech Enterprise

**PRICING INFORMATION:** All sessions may be ordered individually or...

**PURCHASE THE COMPLETE CONFERENCE SET FOR \$1349.00 AND SAVE OVER 40%! Complete package comes in attractive storage albums at no extra charge. Free CD Storage album with each 12 CDs purchased.**

**PURCHASE THE COMPLETE CONFERENCE AUDIO CD SET WITH THE ALL AVAILABLE HANDOUTS ON CD-ROM FOR \$1495**

**PURCHASE THE COMPLETE COMPLETE CONFERENCE SET OF HANDOUTS ON CD-ROM FOR \$195**

**ORDER:**

**When ordering, please identify program by #240606**

**BY PHONE:** With your credit card, please call: (800) 747-8069; (818) 957-0874 - 8:30-4:00 PST, Mon – Fri.

**BY MAIL:** Complete this form, with payment to: **Content Management Corp., 3043 Foothill Blvd., Suite #2, La Crescenta, CA 91214**

**BY FAX:** FAX your order form with credit card information to: (818) 957-0876 24 hours/day; 7 days/week

**ON-LINE:** visit our secure order site at: <http://www.softconference.com/240606> **FOR HANDOUTS, PLEASE VISIT THE WEB-SITE**

**BY EMAIL:** Submit your order with credit card information to: [craig@cmcgc.com](mailto:craig@cmcgc.com)

**MAIL ORDER FORM - BIO 2004**

All CDs are covered by a lifetime guarantee - Defective CDs will be replaced free-of-charge \* ALL SALES FINAL AFTER 30 DAYS - All returned CDs within 30 days subject to 25% restocking fee \* We accept VISA, MC, AmExpress, & personal/company checks payable to **CONTENT MANAGEMENT CORP.**

\_\_\_\_\_ Total Audio CD Selections at \$12 Each.....\$ \_\_\_\_\_

\_\_\_\_\_ Total "AB" Audio CD Selections at \$24 Each.....\$ \_\_\_\_\_

\_\_\_\_\_ Total Audio CD Complete Convention Sets @\$1349 .\$. \_\_\_\_\_

\_\_\_\_\_ Audio CD Complete Sets/Handout CD-ROM \$1499...\$ \_\_\_\_\_

\_\_\_\_\_ complete Handout CD-ROMs @ \$195.....\$ \_\_\_\_\_

**Mailing & Handl. \$1 per CD to a \$10 max**.....\$ \_\_\_\_\_

**Foreign Mail/Hand. - Add \$2/CD to \$75 max**.....\$ \_\_\_\_\_

**TOTAL AMOUNT...ALL PRICES ARE IN U.S. FUNDS**.....\$ \_\_\_\_\_

Check  VISA  MC  AmEx Exp. Date \_\_\_\_\_

Credit Card Acct Number \_\_\_\_\_

Signature \_\_\_\_\_

Ship to: Name \_\_\_\_\_

Company \_\_\_\_\_

Address \_\_\_\_\_

City/State/Zip \_\_\_\_\_

Daytime Phone Number \_\_\_\_\_

email address \_\_\_\_\_



**CONTENT MANAGEMENT Corp.**